克隆尼辛的抗癌活性作为MCF-7乳腺癌细胞系的替代疗法
Samann Said Taha Said Ahmed1, Zirak Faqe Ahmed Abdulrahman2, Ramadhan Tayeb Othman3
1Biology Department, College of Science, University of Duhok, Duhok, Kurdistan Region-Iraq. samanvet2016@gmail.com.
Cellular and molecular biology (Noisy-le-Grand, France)
|October 9, 2023
概括
研究人员克隆了Nisa基因以产生Nisin,一种抗微生物,在体外证明了它对乳腺癌细胞的选择性抗癌作用. 需要进一步的研究来探索其在体内和组合疗法中的治疗潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 癌症是全球主要的死亡原因,传统化疗面临诸如非特异性毒性和耐药性等挑战.
- 越来越需要新的,有针对性的抗癌疗法来克服现有治疗方法的局限性.
- 乳腺癌是女性中最常见的癌症,这凸显了有效治疗策略的紧迫性.
研究的目的:
- 克隆Nisa基因和合成Nisin,一种抗微生物,用于潜在的抗癌应用.
- 评估Nisin在MCF-7乳腺癌细胞系上的体外抗增殖和细胞毒性作用.
主要方法:
- 吉布森克隆被用来分离和克隆Nisa基因.
- 一个无细胞合成系统被用于Nisin的生产,其次是蛋白质净化.
- 使用MTT试验来确定Nisin的抗增殖活性,并通过酸/酸染色评估细胞活力.
主要成果:
- 他们成功地分离了NisA基因,克隆了NisA基因,并净化了Nisin.
- 尼辛对MCF-7乳腺癌细胞系表现出显著和选择性的细胞毒性,其IC50值为11.68μg/ml.
- 在体外研究证实了Nisa基因产品对乳腺癌细胞的抗增殖作用.
结论:
- 尼斯A基因产物Nisin在乳腺癌的治疗中表现出有前途的体外抗癌活性.
- 进一步的体内研究和对组合疗法的调查是有必要的,以探索Nisin的临床潜力.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


